Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing breakthrough therapies to address pressing unmet medical needs, particularly in the realm of autoimmune disorders. Its flagship candidate, KPL-404, is a monoclonal antibody designed to effectively modulate immune responses, positioning Kiniksa at the forefront of promising therapeutic advancements. The company boasts a strong clinical pipeline supported by strategic partnerships that enhance its research and development capabilities. With a dedication to transforming treatment paradigms and a robust growth trajectory, Kiniksa represents an attractive opportunity for institutional investors seeking impactful investments in the evolving healthcare landscape.
| Revenue (TTM) | $945.96M |
| Gross Profit (TTM) | $513.39M |
| EBITDA | $132.36M |
| Operating Margin | 19.00% |
| Return on Equity | 17.60% |
| Return on Assets | 9.62% |
| Revenue/Share (TTM) | $12.27 |
| Book Value | $9.05 |
| Price-to-Book | 9.79 |
| Price-to-Sales (TTM) | 7.80 |
| EV/Revenue | 6.76 |
| EV/EBITDA | 48.30 |
| Quarterly Earnings Growth (YoY) | 143.50% |
| Quarterly Revenue Growth (YoY) | 58.10% |
| Shares Outstanding | $48.84M |
| Float | $40.62M |
| % Insiders | 3.46% |
| % Institutions | 101.99% |
Volatility is currently expanding
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Kiniksa raised 2026 revenue guidance to over $1.045 billion. ARCALYST penetration among multiple recurrence patients reached 23%.
Kiniksa Pharmaceuticals International NASDAQ: KNSA raised its full-year 2026 revenue guidance after reporting third-quarter ARCALYST revenue growth of 58% year over year, as the company continued to expand use of the drug for recurrent pericarditis and advance its clinical pipeline.
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.23 per share a year ago.
– ARCALYST ® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion – – KPL-387 pivotal Phase 3 data expected in 2H 2027 – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported third quarter 2026 financial results and recent portfolio execution. “Kiniksa continues to build a leading IL-1α and IL-1β inhibition franchise, driven by the commercialization of ARCALYST in recurrent pericarditis.
LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern Time to report its third quarter 2026 financial results and recent portfolio execution.
KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.
LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time.
LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 9:00 a.m. Eastern Time.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on KNSA and any ticker you trade — then tracks every position and per-strategy win rate.
